NeoGenomics Inc (NEO)
16.87
-1.29
(-7.10%)
USD |
NASDAQ |
Mar 24, 16:00
17.21
+0.34
(+2.02%)
After-Hours: 20:00
Key Stats
Price and Performance | |
---|---|
Market Cap | 2.150B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -5.44% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 4.111 |
Price to Book Value | 2.154 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.5364 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 89.23% |
News
Headline
Wire
Time (ET)
MT Newswires
03/22 11:08
Yahoo
03/22 08:00
NeoGenomics' (NASDAQ:NEO) growing losses don't faze investors as the stock grows 4.7% this past week
Yahoo
03/21 08:06
Globe Newswire
03/17 17:00
Accesswire
03/16 07:00
Yahoo
03/13 07:00
MT Newswires
03/03 11:10
Events
DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
04/27/2023* | 08:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
04/27/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
02/23/2023 | 08:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
02/23/2023 | -- | Results | Q4 2022 | -0.06 | -0.16 | 63.55% | |
11/08/2022 | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
11/08/2022 | -- | Results | Q3 2022 | -0.14 | -0.21 | 32.09% | |
08/09/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
08/09/2022 | -- | Results | Q2 2022 | -0.16 | -0.23 | 29.01% |
*Estimated Date/Time
Earnings
Profile
Edit
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services. |
URL | https://www.neogenomics.com |
Investor Relations URL | https://ir.neogenomics.com/ |
HQ State/Province | Florida |
Sector | Healthcare |
Industry | Diagnostics & Research |
Equity Style | Small Cap/Blend |
Next Earnings Release | Apr. 27, 2023 (est.) |
Last Earnings Release | Feb. 23, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Dividends
Dividend Per Share (TTM) | -- |
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
Yield to Market | 0.00 |
Yield to Sector | 0.00 |
Yield to Industry | 0.00 |
Last Dividend Amt. | -- |
Dividend Frequency | -- |
Last Ex-Dividend Date | -- |
Yield (TTM) | 0.00% |
Forward Yield | -- |
Payout Ratio | 0.00% |
Cash Payout Ratio | 0.00% |
Consistent Payer (5Y) | No |
Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 24, 2023.
Fundamentals
Revenue (TTM) | 509.73M |
Total Expenses (TTM) | 662.84M |
Net Income (TTM) | -144.25M |
Total Assets (Quarterly) | 1.740B |
Total Liabilities (Quarterly) | 742.01M |
Shareholders Equity (Quarterly) | 998.02M |
Cash from Operations (TTM) | -65.99M |
Cash from Investing (TTM) | 0.517M |
Cash from Financing (TTM) | 11.83M |
Ratings
Profile
Edit
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services. |
URL | https://www.neogenomics.com |
Investor Relations URL | https://ir.neogenomics.com/ |
HQ State/Province | Florida |
Sector | Healthcare |
Industry | Diagnostics & Research |
Equity Style | Small Cap/Blend |
Next Earnings Release | Apr. 27, 2023 (est.) |
Last Earnings Release | Feb. 23, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ownership
Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Other Resources
Whale Wisdom | 13F Filings |
Seeking Alpha | Call Transcripts |
Nasdaq | Insider Trading |
Nasdaq | Institutional Ownership |
Nasdaq | Option Chain |
SEC | SEC Filings |
NEO Tweets |